In a 76‑year‑old man with type 2 diabetes and elevated hemoglobin A1c, currently on metformin 1000 mg BID, glipizide extended‑release 10 mg BID, and sitagliptin (Januvia) 100 mg daily, what changes to his regimen are recommended to achieve better glycemic control?

Discontinue Glipizide and Add Basal Insulin to Achieve Target Glycemic Control

In this 76-year-old man with HbA1c 9.6% on triple oral therapy, you should stop glipizide immediately, continue metformin and sitagliptin, and initiate basal insulin at 10 units nightly (or 0.1–0.2 units/kg) to achieve adequate glycemic control. 1

---

Rationale for Immediate Insulin Initiation

• When HbA1c is ≥9.0%, the American Diabetes Association recommends starting insulin (with or without additional agents) because oral agents alone typically lower HbA1c by only 0.9–1.1%—insufficient to reach the target of <7%. 2
• This patient's HbA1c of 9.6% indicates severe hyperglycemia that warrants aggressive therapy; delaying insulin while trialing additional oral agents prolongs hyperglycemic exposure and raises complication risk. 2

---

Why Glipizide Must Be Discontinued

• Sulfonylureas (glipizide) should be stopped when insulin is added, especially in patients ≥65 years or with any degree of renal impairment, to avoid severe hypoglycemia. 2
• Glipizide contributes minimal additional benefit at this stage while substantially increasing hypoglycemia risk, especially when combined with insulin therapy. 2
• Compared with metformin, sulfonylureas are associated with a two-fold higher all-cause mortality (hazard ratio ≈2.08) and a seven-fold higher risk of major hypoglycemic events (hazard ratio ≈7.14). 2

---

Metformin and Sitagliptin Should Be Continued

• Metformin must remain as the foundation of therapy even when insulin is added because it lowers insulin requirements by 20–30%, mitigates insulin-associated weight gain, confers cardiovascular mortality benefit, and carries minimal hypoglycemia risk. 2
• The current metformin dose of 1000 mg twice daily (2000 mg total) is optimal; doses above 2000 mg add little benefit and increase gastrointestinal intolerance. 2
• Sitagliptin should be continued because it complements the other agents without significant adverse effects and provides an additional 0.5–0.8% HbA1c reduction when combined with metformin and insulin. 2
• Sitagliptin is generally well-tolerated and has a lower risk of hypoglycemia compared to sulfonylureas. 3, 4

---

Basal Insulin Initiation and Titration Protocol

• Starting dose: Begin basal insulin (NPH or a long-acting analog such as glargine or degludec) at 10 units once daily at bedtime or calculate 0.1–0.2 units/kg body weight. 1
• Titration: Increase the dose by 2–4 units every 3 days until fasting glucose consistently reaches 80–130 mg/dL without hypoglycemia. 1
• Hypoglycemia management: If hypoglycemia occurs, identify the cause and reduce the insulin dose by 10–20% immediately. 1

---

Monitoring and Follow-Up

• Re-measure HbA1c at 3 months after insulin initiation; this is the longest acceptable interval before assessing effectiveness and avoiding therapeutic inertia. 2
• The glycemic target for most adults without complications is HbA1c <7% to reduce micro- and macrovascular complications. 2
• Check estimated glomerular filtration rate (eGFR) at baseline and annually to ensure continued safety of metformin (contraindicated when eGFR <30 mL/min/1.73 m²). 2
• Periodically assess vitamin B12 levels in patients on long-term metformin, especially if anemia or peripheral neuropathy develop. 2

---

Treatment Intensification if HbA1c Remains >7% After 3 Months

• If HbA1c is still >7% after 3 months of optimized metformin + sitagliptin + basal insulin, add a GLP-1 receptor agonist (e.g., semaglutide, liraglutide, dulaglutide) rather than further increasing insulin dose. 1, 2
• GLP-1 receptor agonists provide an additional 0.6–0.8% HbA1c reduction when added to existing therapy, promote 2–5 kg weight loss, carry minimal hypoglycemia risk when not combined with sulfonylureas, and have proven cardiovascular benefit. 2
• Do not combine GLP-1 receptor agonists with DPP-4 inhibitors (sitagliptin); no additional glucose-lowering benefit has been demonstrated, so sitagliptin should be discontinued if a GLP-1 agonist is added. 2

---

Critical Pitfalls to Avoid

• Do not continue glipizide when insulin is added; this combination markedly raises the risk of severe hypoglycemia and must be avoided. 2
• Do not discontinue metformin when insulin is initiated unless contraindicated; it remains a foundational therapy throughout intensification. 2
• Avoid therapeutic inertia: intensify therapy within 3 months if HbA1c remains above target, as delays prolong hyperglycemia exposure and increase complication risk. 2
• Do not add additional sulfonylureas to the regimen; they lack the cardiovascular benefits of GLP-1 receptor agonists or SGLT2 inhibitors and markedly increase hypoglycemia risk. 2

---

Expected Clinical Outcomes

• Weeks 1–4: Fasting glucose typically normalizes to 80–130 mg/dL as basal insulin is titrated. 2
• Month 3: Dual therapy (metformin + sitagliptin + basal insulin) usually reduces HbA1c by 2–3%, often achieving <7%; if not, add a GLP-1 receptor agonist. 2
• Insulin may cause a modest weight gain of 2–4 kg; this effect can be mitigated by continued metformin and, if needed, addition of a GLP-1 receptor agonist. 2